King's College London

Funding Information: The authors acknowledge grant support from the International Parkinson and Movement Disorder Society to plan, develop, and validate the English version of the MDS‐NMS in an international study from where the data for the current analyses were obtained. The authors acknowledge support from the NIHR Clinical Research Network and CRN‐supported staff for data collection in NHS clinics and of the UCL/H Biomedical Research Council. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. Funding Information: In the past year D.v.W. has received speaker fees from Bial and Britannia pharmaceuticals, and research grants from NIHR BRC and CHDI; S.R. has nothing to disclose; A.S. has nothing to disclose; A.R. has received support from the National institute of Health Research (NIHR) Clinical Research Network (CRN) South London, Guy's Hospital, Great Maze Pond, London UK and International Parkinson and Movement Disorder Society (MDS); P.M.M. has nothing to disclose; In the past year D.W. has received research funding or support from Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Therapeutic Research Initiative (ATRI), Alzheimer's Disease Cooperative Study (ADCS), International Parkinson and Movement Disorder Society (IPMDS), National Institute on Health (NIH), Parkinson's Foundation; U.S. Department of Veterans Affairs and Acadia Pharmaceuticals; honoraria for consultancy from Acadia Pharmaceuticals, Alkahest, Aptinyx, Cerevel Therapeutics, CHDI Foundation, Clexio, Clintrex LLC (Otsuka), EcoR1 Capital, Eisai, Ferring, Gray Matter Technologies, Great Lake Neurotechnologies, Intra‐Cellular Therapies, Janssen, Merck, Sage, Scion, Signant Health and Vanda; and license fee payments from the University of Pennsylvania for the QUIP and QUIP‐RS. K.R.C. reports advisory board for AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Zambon, Profile Pharma, Synovion, Roche, and Therevance, Scion, as well as honoraria for lectures for AbbVie, Britannia, UCB, Zambon, Novartis, Boeringer Ingelheim, Bial, Kyowa Kirin, SK Pharma, and frants (Investigator Initiated) from Bial, EU Horizon 2020, Parkinson's UK, NIHR, Parkinson's Foundation, Wellcome Trust, and royalties or licenses (ongoing) from Oxford (book), Cambridge publishers (book), MAPI institute (KPPS, PDSS 2), and payment for expert testimony for the General Medical Council (UK). Publisher Copyright: © 2022 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society.